Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical oxybutynin 10% gel vs aluminum chloride 20% for primary hyperhidrosis
IRCT20221110056463N2Phase 4Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of oxybutynin in Primary hyperhidrosis (PH) (2 arms), sponsored by Kerman University of Medical Sciences. Started Nov 2022; status: completed.
02
Drugs
oxybutynin
03
Conditions
Primary hyperhidrosis (PH)
Beyond the preview
Go deeper on IRCT20221110056463N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221110056463N2.